Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NVS

The 5 Safest Stocks You Can Buy in 2023

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

StockNews.com

$1,000 Invested in These 3 Stocks Could Make You Richer in 2023

Hot economic data and rekindled price pressures are expected to keep the stock market highly volatile, with the Fed minutes signaling continued rate hikes in upcoming meetings. Amid this backdrop, investing $1,000 in fundamentally sound and dividend-paying stocks Walmart (WMT), Novartis (NVS), and Albertsons (ACI) could make you richer this…

StockNews.com

2 Stable Stocks to Add to Your Portfolio in 2023

Amid soaring concerns over an impending Fed-induced recession, the stock market could remain volatile in the near future. Against this backdrop, investors could add stable stocks Johnson & Johnson (JNJ) and Novartis (NVS) to their portfolios in 2023 to garner good returns. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

The 3 Best Pharma Stocks to Buy for Big Gains in 2023

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

StockNews.com

3 Stable Stocks That Could Help Pay Your Bills in 2023

Despite eased inflation, the robust jobs report raised the prospect of progressive rate hikes. With anxiety escalating about the possibility of a Fed-induced recession, the market volatility is expected to remain elevated in the near future. Hence, investors could consider fundamentally sound and stable stocks Novartis (NVS), Descartes Systems (DSGX),…

StockNews.com

5 Top Stocks to Buy for 2023

The stock market witnessed a solid start this year amid improving investors’ optimism. Moreover, experts see increased chances of a soft landing. So, fundamentally strong stocks Merck (MRK), Novartis (NVS), Sysco (SYY), Progress Software (PRGS), and LSI Industries (LYTS) could be solid buys now. These stocks pay consistent dividends. Read…

StockNews.com

2 Stable Stocks You Can Buy Now for Under $100

Despite the recent positive macro data, the recession possibility remains as the Federal Reserve is expected to keep hiking rates until its target is met. So, dividend-paying healthcare stocks Novartis (NVS) and Takeda Pharmaceutical (TAK) could be stable investment options to safeguard your portfolios. These stocks are trading under $100.…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Reliable Stocks That Could Help You Make Money in 2023

The stock market witnessed a decent rally in January, with cooling inflationary pressures reducing recession fears. However, the Fed’s attempts to bring inflation down to its 2% target could hurt economic growth. Hence, it could be wise to invest in shares of Johnson & Johnson (JNJ), Novartis (NVS), and LCNB…

StockNews.com

3 Stocks It Is Time to Buy Now

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain its 2% target. However, a potential slowdown in monetary policy tightening is opening the path for quality stocks to recover. Therefore, investors should consider buying fundamentally sound stocks Merck & Co. (MRK), Novartis (NVS), and…

StockNews.com

3 Safe Stocks to Buy in an Unpredictable Market

The Fed’s intention to continue raising interest rates, disappointing economic data, and a weak earnings season could keep the stock market highly volatile. Hence, investing in quality stocks Microsoft (MSFT), Johnson (JNJ), and Novartis (NVS) could be safe. Continue reading.

StockNews.com

2 Pharma Stocks to Buy Now for Big Gains

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

StockNews.com

The 3 Best Large-Cap Stocks to Buy Now and Hold Forever

Although the latest inflation and employment reports indicate a resilient economy, the Fed’s persistence to keep interest rates high has caused widespread concerns about an economic slowdown. With uncertainties surrounding the economy, we think it could be wise to buy and hold large-cap stocks Merck & Co. (MRK), Coca-Cola (KO),…

StockNews.com

1 Large-Cap Stock You Should Purchase This Week

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…

StockNews.com

3 Must Have Pharma Stocks in January 2023

Rising rates of chronic diseases, an aging population, and increasing healthcare spending should drive the pharma industry’s growth in the upcoming years. Moreover, pharma companies perform steadily regardless of economic conditions due to the inelastic demand for their products. Therefore, it could be wise to invest in fundamentally strong pharma…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharmaceutical Stocks Under $100 to Buy This Week

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

StockNews.com

2 Stable Stocks Every Investor Should Be Watching Now

The stock market is witnessing heightened volatility due to the multi-decade high inflation and the Fed’s rate hikes. Given the uncertainties ahead, fundamentally sound stocks Johnson & Johnson (JNJ) and Novartis (NVS), which seem relatively stable, might be ideal additions to your watchlist. Keep reading….

Benzinga

Novartis Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Novartis. Looking at options history for Novartis (NYSE:NVS) we detected 21 strange trades.

Daily Record

Rylan Clark first met new love interest Declan Doyle on The X Factor decade ago

The TV personality and Declan, who is the ex of Geordie Shore star Nathan Henry, have been spotted out and about looking cosy in recent weeks.

Get all your
news in one place.

100’s of premium titles.
One news app.

Daily Mirror

Rylan Clark first met his new love interest Declan Doyle on The X Factor 10 years ago

Rylan Clark and his rumoured new boyfriend Declan Doyle are said to be preparing to meet each others parents - 10 years on from first meeting thanks to The X Factor way back in 2012

Benzinga

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Benzinga

Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines

Novartis AG (NYSE:NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension…

Benzinga

Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria

Novartis AG (NYSE:NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an aim to eliminate these diseases. "Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done," CEO Vas Narasimhan said. Novartis…

Benzinga

FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use

The FDA granted accelerated approval to Novartis AG's (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer.…

StockNews.com

5 Durable Stocks to Strengthen Your Portfolio

Given the current market turmoil caused due to surging inflation and the Fed’s aggressive interest rate hikes to bring prices down, it could be wise to invest in stocks that do not fluctuate significantly in adverse market conditions. The solid stability of Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), Marubeni…

Birmingham Post

Work starts on National Veterinary Services' new Stoke-on-Trent warehouse

Winvic Construction has won the contract for the 253,000 sq ft unit at St Modwen Park Stoke Central on Festival Park

1 2 3

People

Mangeet Kaur BounsMangeet

595 stories

Ronan keating

356 stories

Sristi Suman Jayaswal

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.